戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Postvoid FDG PET images substantially reduced the tracer
2 th three additional cases detected using the postvoid images.
3 76%) were detected by FDG PET without use of postvoid imaging (i.e., interpreted as grade 2 or 3).
4                      In the 11 patients with postvoid imaging, all 11 cancers (100%) were detected.
5                 Three patients had increased postvoid residual (PVR).
6                            Uroflowmetry with postvoid residual assessment is recommended for at speci
7 e culture, measurement of hemoglobin A1c and postvoid residual bladder volume, and a survey of diabet
8 er score, decreased flow rate, and increased postvoid residual have all been linked to progression to
9 and physical examination, urine culture, and postvoid residual measurement, does not identify other c
10 value for and do not correlate with elevated postvoid residual urine (PVR).
11  There seems to be an associated increase in postvoid residual urine volume by the combinations, but
12                                              Postvoid residual urine volumes and urine flow rates wer
13  be considered in the absence of significant postvoid residual urine volumes.
14                   Prolonged voiding time and postvoid residual urine were also observed.
15 ed by 38%, prostate volume decreased by 20%, postvoid residual volume decreased by 30 mL, and IIEF sc
16                                            A postvoid residual volume should be measured prior to com
17 d significantly reduced bladder capacity and postvoid residual volume than diabetic rats injected wit
18 t several trials demonstrated an increase in postvoid residual volume with anticholinergic therapy.
19 ow rate, 6 mL/sec +/- 10 (155% +/- 293); and postvoid residual volume, 70 mL +/- 121 (48% +/- 81) (P
20 lity of life (QOL) score, peak urinary flow, postvoid residual volume, International Index Erectile F
21 ty-of-life score, maximum urinary flow rate, postvoid residual volume, prostate-specific antigen (PSA
22 s of urinary bother, nocturia, peak uroflow, postvoid residual volume, prostate-specific antigen leve
23 n (6-12 weeks) and include only men with low postvoid residual volumes at baseline, and the results a
24 rmed to assess patients with suspected large postvoid residual volumes.
25                                              Postvoid scans were also obtained in 11 patients to mini